Many public biopharmaceutical companies have taken advantage of the ongoing capital markets recovery in 2024 by raising money through follow-on public offerings (FOPOs) after announcing key research and development, regulatory or other business milestones. Revolution Medicines and NewAmsterdam Pharma are among drug developers who closed significant FOPOs in December after important clinical trial readouts, grossing $862.5m and $479m, respectively.
These offerings continue a trend seen in Biomedtracker data through the third quarter, which showed that biopharma companies raised $23bn through FOPOs during the first three quarters of 2024,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?